Beta Agonist Lung Injury TrIal-2 (BALTI-2) trial protocol : a randomised, double-blind, placebo-controlled of intravenous infusion of salbutamol in the acute respiratory distress syndrome
Perkins, Gavin D., Gates, Simon, Lamb, S. E. (Sallie E.), McCabe, Chris (Christopher J.), 1967-, Young, Duncan S. and Smith, F. Gao (Fang Gao). (2011) Beta Agonist Lung Injury TrIal-2 (BALTI-2) trial protocol : a randomised, double-blind, placebo-controlled of intravenous infusion of salbutamol in the acute respiratory distress syndrome. Trials, Vol.12 (No.1). p. 113. ISSN 1745-6215
WRAP_Perkins_Beta_agonist_lung.pdf - Published Version - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
Available under License Creative Commons Attribution.
Official URL: http://dx.doi.org/10.1186/1745-6215-12-113
Background: The Acute Respiratory Distress Syndrome (ARDS) is a common cause of respiratory failure in critically ill patients. Experimental studies suggest that treatment with beta agonists may be helpful in ARDS. The Beta Agonist Lung Injury TrIal (BALTI-2) is a multicentre, pragmatic, randomised, double-blind, placebo-controlled clinical trial which aims to determine if sustained treatment with intravenous (IV) salbutamol will improve survival in ARDS.
Methods/Design: Patients fulfilling the American-European Consensus Conference Definition of ARDS will be randomised in a 1: 1 ratio to receive an IV infusion either of salbutamol (15 mu g kg ideal body weight(-1) hr(-1)) or placebo (0.9% sodium chloride solution), for a maximum of seven days. Allocation to randomised groups will use minimisation to ensure balance with respect to hospital of recruitment, age group (<64, 65-84, >85 years) and PaO(2)/FiO(2) ratio (<= 6.7, 6.8- 13.2, >= 13.3 kPa). Data will be recorded by participating ICUs until hospital discharge, and all surviving patients will be followed up by post at six and twelve months post randomisation. The primary outcome is mortality at 28 days after randomisation; secondary outcomes are mortality in ICU, mortality in hospital, number of ventilator-free days, number of organ failure-free days, mortality at twelve months post-randomisation, quality of life at six and twelve months, length of stay in ICU, length of stay in hospital, adverse effects (tachycardia, arrhythmia or other side effects sufficient to stop treatment drug). 1,334 patients will be recruited from about fifty ICUs in the UK. An economic evaluation will be conducted alongside the trial.
|Item Type:||Journal Article|
|Subjects:||R Medicine > RC Internal medicine|
|Divisions:||Faculty of Medicine > Warwick Medical School > Health Sciences
Faculty of Medicine > Warwick Medical School
|Library of Congress Subject Headings (LCSH):||Respiratory distress syndrome, Adult -- Treatment, Adrenergic beta agonists, Clinical trials|
|Journal or Publication Title:||Trials|
|Official Date:||9 May 2011|
|Page Range:||p. 113|
|Access rights to Published version:||Open Access|
|Funder:||Medical Research Council (Great Britain) (MRC), Intensive Care Society (Great Britain) (ICS), National Institute for Health Research (Great Britain) (NIHR)|
1. Ware LB, Matthay MA: The acute respiratory distress syndrome. N Engl J
Actions (login required)